Search
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. … [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Mixtures: OCIDERM-N, CINOLON-NHexafluronium
go.drugbank.com/drugs/DB00941ApprovedHexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigational[A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short
Synonyms: 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)Products: Suxamethonium Aguettant 10 mg/ml Injektionslösung in einer FertigspritzeFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalFactor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade.
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigationalSotatercept is an activin signalling inhibitor. … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Magnesium Aluminum Silicate
go.drugbank.com/drugs/DB11230ApprovedWithdrawnIt is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.[L43862] … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt
Dorocubicel
go.drugbank.com/drugs/DB19448Approved[L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.
Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoules